Sumitomo Mitsui Trust Holdings, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $134 Billion
- Q2 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 14,800 shares of CPRX stock, worth $315,980. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,800
Previous 26,700
44.57%
Holding current value
$315,980
Previous $425,000
46.12%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$399 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$195 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$173 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$129 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$64.1 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.2B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...